ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2019

Strong sales growth during June; Zinzino based revenue increased 30% and the total group revenue with a total of 23% compared with the previous year. Zinzino based revenue for the second quarter 2019 increased with 31% and the total revenue with 23% compared with previous year.

The revenue in June for Zinzino's sales markets increased by 30% to MSEK 52.4 (40.3) due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 23% and amounted to MSEK 4.6 (5.9) due to high level of internal production during the month. Overall the Group increased revenues by 23% to MSEK 57.0 (46.3) compared with the previous year. 

The second quarter of 2019 became the strongest quarter in Zinzino based sales so far in the company´s history; the revenue in April - June increased 31% to MSEK 164.3 (125.7) compared with previous year. Total revenue increased by 23% to MSEK 178.3 (144.5)
  

Accumulated revenue for January – June 2019 increased by 22% MSEK 346,5 (284,8).
   

Revenues distributed as follows:

The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00,
email: certifiedadviser@penser.se 

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 13:00 the 10th of July, 2019.
  

Zinzino AB (publ.) is a direct sales company that operates throughout Europe, North America and Australia. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns the Norwegian company BioActie Foods AS and the research and production unit Faun Pharma AS. Zinzino has more than 120 employees and currently trades in 34 markets across Europe, North America and Australia. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Brisbane. Zinzino is a public company listed on Nasdaq First North.